暂无分享,去创建一个
Zina M. Ibrahim | Zina Ibrahim | Richard Dobson | Ehtesham Iqbal | Matthew Broadbent | Robert Stewart | Risha Govind | Alvin Romero | Olubanke Dzahini | Tanya Smith | Chi-Hun Kim | Nomi Werbeloff | R. Dobson | N. Werbeloff | C. Kim | Robert J Stewart | M. Broadbent | Risha Govind | Ehtesham Iqbal | O. Dzahini | A. Romero | Tanya Smith | R. Govind | R. Stewart
[1] P. Vuopio,et al. Agranulocytosis in patients treated with clozapine , 1977, Acta psychiatrica Scandinavica.
[2] R. Poland,et al. Ethnicity and psychopharmacology , 1986, Culture, medicine and psychiatry.
[3] J. Lieberman,et al. Update on the clinical efficacy and side effects of clozapine. , 1991, Schizophrenia bulletin.
[4] P. Krupp,et al. Clozapine-Associated Agranulocytosis: Risk and Aetiology , 1992, British Journal of Psychiatry.
[5] R. Leadbetter,et al. Clozapine-induced weight gain: prevalence and clinical relevance. , 1992, The American journal of psychiatry.
[6] J. Lohr,et al. Smoking and schizophrenia , 1992, Schizophrenia Research.
[7] J. Lieberman,et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. , 1993, The New England journal of medicine.
[8] J. Rapoport,et al. An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. , 1994, Journal of the American Academy of Child and Adolescent Psychiatry.
[9] J. Rapoport,et al. Childhood-onset schizophrenia: A double-blind clozapine-haloperidol comparison , 1996 .
[10] S. Stahl,et al. Book Review: Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 2nd Edition , 1996 .
[11] Abraham Weizman,et al. An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia , 1997, British Journal of Psychiatry.
[12] P. Corey,et al. Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .
[13] C. Mazure,et al. Management of the adverse effects of clozapine. , 1998, Schizophrenia bulletin.
[14] J. Rapoport,et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. , 1999, Journal of child and adolescent psychopharmacology.
[15] Del D. Miller,et al. Review and management of clozapine side effects. , 2000, The Journal of clinical psychiatry.
[16] R. McCreadie,et al. Cigarette smoking and schizophrenia , 2000 .
[17] M. Angermeyer,et al. Patients' and relatives' assessment of clozapine treatment , 2001, Psychological Medicine.
[18] M. Rademaker. Do Women Have More Adverse Drug Reactions? , 2001, American journal of clinical dermatology.
[19] M. Anthony,et al. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I. , 2002, Journal of women's health & gender-based medicine.
[20] H. Nasrallah,et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. , 2002, The Journal of clinical psychiatry.
[21] P. Schulte. What is an Adequate Trial with Clozapine? , 2003, Clinical pharmacokinetics.
[22] M. Olkinuora,et al. Agranulocytosis during treatment with clozapine , 1977, European Journal of Clinical Pharmacology.
[23] M. Pirmohamed,et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.
[24] L. Citrome. The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. , 2004, Drugs of today.
[25] H. Remschmidt,et al. Chart review for potential features of myocarditis, pericarditis, and cardiomyopathy in children and adolescents treated with clozapine. , 2004, Journal of child and adolescent psychopharmacology.
[26] D. Cohen. Atypical Antipsychotics and New Onset Diabetes mellitus , 2004, Pharmacopsychiatry.
[27] S. Kumra,et al. Hematological adverse events in clozapine-treated children and adolescents. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.
[28] J. Lieberman,et al. Clinical profile of clozapine: Adverse reactions and agranulocytosis , 2005, Psychiatric Quarterly.
[29] B. Herpertz-Dahlmann,et al. Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. , 2006, Journal of child and adolescent psychopharmacology.
[30] B. Disilvio,et al. Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. , 2007, Life sciences.
[31] T. Furukawa,et al. Regulation of cardiac ion channels via non-genomic action of sex steroid hormones: implication for the gender difference in cardiac arrhythmias. , 2007, Pharmacology & therapeutics.
[32] Julie Kreyenbuhl,et al. Clozapine underutilization and discontinuation in African Americans due to leucopenia. , 2007, Schizophrenia bulletin.
[33] J. McNeil,et al. Clozapine-Associated Myocarditis , 2007, Drug safety.
[34] J. Rapoport,et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.
[35] B. Herpertz-Dahlmann,et al. Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone , 2008, Journal of Neural Transmission.
[36] I. Chaudhry,et al. Ethnicity and psychopharmacology , 2008, Journal of psychopharmacology.
[37] R. Flanagan. Side effects of clozapine and some other psychoactive drugs. , 2008, Current Drug Safety.
[38] Kay A. Hodge,et al. Side-effects and treatment with clozapine: a comparison between the views of consumers and their clinicians. , 2008, International journal of mental health nursing.
[39] E. Russo,et al. The safety of clozapine in the elderly , 2008, Expert opinion on drug safety.
[40] Shu-Feng Zhou,et al. Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2 , 2009, The AAPS Journal.
[41] David Taylor,et al. Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection. , 2009, The British journal of psychiatry : the journal of mental science.
[42] Graham Thornicroft,et al. The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data , 2009, BMC psychiatry.
[43] C. Correll,et al. Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients , 2010, Neuropsychopharmacology.
[44] A. Mortimer,et al. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world. , 2010, Clinical schizophrenia & related psychoses.
[45] B. Stricker,et al. Sex-related differences in hospital admissions attributed to adverse drug reactions in the Netherlands. , 2011, British journal of clinical pharmacology.
[46] D. Classen,et al. 'Global trigger tool' shows that adverse events in hospitals may be ten times greater than previously measured. , 2011, Health affairs.
[47] C Hofer-Dueckelmann,et al. Adverse drug reactions (ADRs) associated with hospital admissions - elderly female patients are at highest risk. , 2011, International journal of clinical pharmacology and therapeutics.
[48] M. Raja. Clozapine safety, 35 years later. , 2011, Current drug safety.
[49] R. Altman,et al. Data-Driven Prediction of Drug Effects and Interactions , 2012, Science Translational Medicine.
[50] M. Picchioni,et al. A systematic review of the evidence of clozapine's anti-aggressive effects. , 2012, The international journal of neuropsychopharmacology.
[51] F. Dickerson,et al. Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999-2011. , 2012, Psychiatric services.
[52] Jennifer H. Martin,et al. Smoking and drug interactions , 2013 .
[53] S. Frangou,et al. Systematic review of the efficacy and tolerability of Clozapine in the treatment of youth with early onset schizophrenia , 2014, European psychiatry.
[54] E. Russo,et al. Rare and very rare adverse effects of clozapine , 2015, Neuropsychiatric disease and treatment.
[55] F. Gaughran,et al. Glasgow Antipsychotic Side-effects Scale for Clozapine — Development and validation of a clozapine-specific side-effects scale , 2015, Schizophrenia Research.
[56] Matthew Broadbent,et al. The Effect of Clozapine on Premature Mortality: An Assessment of Clinical Monitoring and Other Potential Confounders , 2014, Schizophrenia bulletin.
[57] J. MacCabe,et al. Predictors of long-term (≥ 6 months) antipsychotic polypharmacy prescribing in secondary mental healthcare , 2016, Schizophrenia Research.
[58] N. Kar,et al. Clozapine Monitoring in Clinical Practice: Beyond the Mandatory Requirement , 2016, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.
[59] Peer Bork,et al. The SIDER database of drugs and side effects , 2015, Nucleic Acids Res..
[60] Consistency between clinician and patient ratings of clozapine-induced side effects , 2016, Schizophrenia Research.
[61] Andrea C. Fernandes,et al. Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record-derived data resource , 2016, BMJ Open.
[62] Zina M. Ibrahim,et al. ADEPt, a semantically-enriched pipeline for extracting adverse drug events from free-text electronic health records , 2017, PloS one.
[63] G. Gürcan,et al. Side Effects of Clozapine and Their Relationship with Clinical Variables in Patients with Schizophrenia , 2017, European Psychiatry.
[64] R. Dobson,et al. Trajectories of dementia-related cognitive decline in a large mental health records derived patient cohort , 2017, PloS one.
[65] R. Stewart,et al. The Camden & Islington Research Database: Using electronic mental health records for research , 2018, PloS one.